Dermata Therapeutics (NASDAQ:DRMA) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Dermata Therapeutics (NASDAQ:DRMA) from a sell rating to a hold rating in a report released on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e)” rating on shares of Dermata Therapeutics in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Dermata Therapeutics Stock Performance

Shares of DRMA stock opened at $1.18 on Friday. The firm’s 50-day moving average is $1.60 and its 200-day moving average is $2.81. The stock has a market cap of $3.35 million, a price-to-earnings ratio of -0.13 and a beta of 0.60. Dermata Therapeutics has a 52-week low of $1.11 and a 52-week high of $13.20.

Dermata Therapeutics (NASDAQ:DRMA) last issued its earnings results on Thursday, March 26th. The company reported ($1.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.54) by $0.02.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Dermata Therapeutics stock. Clear Street Group Inc. acquired a new position in shares of Dermata Therapeutics, Inc. (NASDAQ:DRMA) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 17,000 shares of the company’s stock, valued at approximately $39,000. Clear Street Group Inc. owned about 0.60% of Dermata Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 8.67% of the company’s stock.

Dermata Therapeutics Company Profile

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.